The Institute for Protein Design at the UW School of Medicine will advance medicine and improve healthcare with an initial $45 million in funding through TED’s The Audacious Project
The Institute for Protein Design will become an innovation hub for new therapeutics for a variety of common, serious diseases. It will also engineer new nanomaterials for industry.
The nanoparticle platform for this respiratory syncytial virus study will be applied to vaccine research on flu, HIV, and more. Seattle startup Icosavax will advance related clinical trials.
Interleukin-2 (IL-2) is a molecule that amps up immune cells to fight off infections. While it is effective, the problem with IL-2 is that it causes a lot of toxicity in patients.
The advance paves the way for building entirely novel, custom-designed antibodies, enzymes and other biologically active proteins.
The Institute for Protein Design at the University of Washington School of Medicine has been awarded $11.3 million from the Open Phi
The ability to build transmembrane proteins opens the way for custom-designing structures that span living cell membranes and perform new tasks.
Two decades ago, the notion of building custom proteins and correctly predicting their structure was a dream.
Computationally designed protein assemblies, which display functions associated with living things, may pose ways to transport therapeutic cargos into cells without using viruses as vehicles.
Gamers will pit their wits against a real-life villain: a food poisoning called aflatoxin that can cause liver cancer and stunting.